Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-17 pm EDT 5-day change 1st Jan Change
132.9 USD +0.17% Intraday chart for Moderna, Inc. +8.32% +33.63%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Moderna Insider Sold Shares Worth $1,912,350, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care Stocks Softer Friday Afternoon MT
Sector Update: Health Care MT
Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech MT
Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program MT
Moderna wins case in patent dispute with Pfizer, BioNTech over COVID shot, FT reports RE
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program MT
Investor Whitefort urges Arbutus Biopharma to halt stock sales, find partner RE
Merck to present new oncology data CF
Investors need more than PPI to make up their minds Our Logo
ANALYST RECOMMENDATIONS : Nike, Roblox, Starbucks, Walmart, Deckers Outdoor... Our Logo
Evercore ISI Initiates Moderna With In Line Rating, $120 Price Target MT
Moderna Insider Sold Shares Worth $1,825,220, According to a Recent SEC Filing MT
Equities Mostly Rise as Traders Parse Fed Officials' Comments, Consumer Sentiment Survey MT
S&P 500, Dow Rise as Traders Parse Fed Officials' Comments, Consumer Sentiment Survey MT
Sector Update: Health Care Stocks Higher Late Afternoon MT
Novavax Surges on $1.2 Billion Sanofi Vaccine Deal MT
Equity Markets Mixed Intraday After Consumer Sentiment Survey MT
Sector Update: Health Care Stocks Advance Friday Afternoon MT
Trending : Moderna's Proposed RSV Vaccine Faces Delayed FDA Review DJ
Top Midday Stories: Biden to Reportedly Quadruple Chinese EV Tariffs; Novavax Shares Soar on Sanofi Deal News; Protesters Try to Break Into Tesla's Plant in Germany; FDA Pushes Back Approval of Moderna Vaccine MT
Moderna: FDA delays review of mRNA-1345 CF
Sector Update: Health Care Stocks Edge Higher Premarket Friday MT
Chart Moderna, Inc.
More charts
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
132.7 USD
Average target price
138.5 USD
Spread / Average Target
+4.40%
Consensus
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. News Moderna, Inc.
  5. Goldman Sachs Adjusts Moderna Price Target to $204 From $206
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW